The study conducted by Kompier et al. [18] showed that mutations in RAS and PIK3CA genes were not markers for recurrence-free survival, progression-free survival, or disease-specific survival in bladder cancer patients. This evidence concerns the gene PIK3CA and urinary bladder carcinoma.